Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates
Advanced Science · 2025
DOI: 10.1002/advs.202410744 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xingyan Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, …. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Ophthalmic Solutions, Macular Degeneration. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Fund of China, Shanghai Science and Technology Program, Development Project of Shanghai Peak Disciplines-Integrative Medicine.
Abstract (Originalsprache)
The advent of biomacromolecules antagonizing vascular endothelial growth factor (VEGF) has revolutionized the treatment of neovascular age‐related macular degeneration (nAMD). However, frequent intravitreal injections of these biomacromolecules impose an enormous burden on patients and create a massive workload for healthcare providers. This causes patients to abandon therapy, ultimately leading to progressive and irreversible vision loss. In order to address this unmet clinical need, a noninvasive treatment for nAMD is developed. An optimized cell‐penetrating peptide derivative, bxy Penetratin (bxyWP), is used to non‐covalently complex with the anti‐VEGF protein aflibercept (AFL) via reversible hydrophobic interaction. The interaction is crucial for AFL delivery, neither impairing the affinity of AFL to pathological VEGF, nor being interfered by endogenous proteins in tear fluids. AFL/bxyWP eye drops exhibit prolonged retention on the eye and excellent absorption into the posterior ocular segment following topical administration, with significant drug distribution to the retina and choroid. In a laser‐induced choroidal neovascularization model on cynomolgus monkeys, AFL/bxyWP eye drops efficiently reduce lesion size and leakage comparable to conventional intravitreal injection of AFL. These results suggest that AFL/bxyWP eye drops are feasible self‐administered treatment for neovascular retinal diseases and potentially become a substitute for intravitreal injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai, 201203, China.
- Eye Institute and Department of Ophthalmology, Eye and ENT Hospital, Fudan University, Shanghai, 200031, China.
- Alephoson Biopharmaceuticals Limited, Hong Kong SAR, 999077, China.
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.
- Quzhou Fudan Institute, Quzhou, 324003, China.
- Shanghai Engineering Research Center of ImmunoTherapeutics, Shanghai, 201203, China.
ORCID-Profile: Gang Wei
Förderung
- National Natural Science Fund of China
- Shanghai Science and Technology Program
- Development Project of Shanghai Peak Disciplines-Integrative Medicine
Zitieren
APA
Fan, X., Jiang, K., Zhao, Y., Lee, B. T., Geng, F., Brelen, M. E., Lu, W., & Wei, G. (2025). Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates. Advanced Science. https://doi.org/10.1002/advs.202410744
Vancouver
Fan X, Jiang K, Zhao Y, Lee BT, Geng F, Brelen ME, et al. Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates. Advanced Science. 2025. doi:10.1002/advs.202410744
BibTeX
@article{Fan2025,
author = {Fan, Xingyan and Jiang, Kuan and Zhao, Yongqian and Lee, Benjamin Tk and Geng, Feiyang and Brelen, Marten E and Lu, Weiyue and Wei, Gang},
title = {Peptide‐Bound Aflibercept Eye Drops for Treatment of Neovascular Age‐Related Macular Degeneration in Nonhuman Primates},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202410744}
}
EUVIMED